Therapeutic implications of new insights into the critical role of VP16 in initiating the earliest stages of HSV reactivation from latency

Future Medicinal Chemistry

Volumn 2, Issue 7, 2010, Pages 1099-1105

  Thompson, Richard L ^a   Sawtell, Nancy M ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; PROTEIN VP16; VALACICLOVIR; VIRUS DNA;

DNA REPLICATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSACTIVATION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; HERPES SIMPLEX; HUMANS; MOLECULAR SEQUENCE DATA; SIMPLEXVIRUS; VIRAL PROTEINS; VIRUS LATENCY;

EID: 77954666283     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.197     Document Type: Review

References (50)

1. Knipe DM. Field's Virology (5th). Lippincott Williams & Wilkins, Philadelphia, PA, USA, 2 (2007).
2. Fuchs J, Celum C, Wang J et al. Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial. J. Infect. Dis. 201(8), 1164-1168 (2010).
3. Zhu J, Hladik F, Woodward A et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat. Med. 15(8), 886-892 (2009).
4. Itzhaki RF, Wozniak MA. Herpes simplex virus type 1 in alzheimer's disease: the enemy within. J. Alzheimers Dis. 13(4), 393-405 (2008).
5. Goodpasture EW. Herpetic infections with special reference to involvement of the nervous system. Medicine 8, 223-235 (1929).
6. Wysocka J, Herr W. The herpes simplex virus vp16-induced complex: the makings of a regulatory switch. Trends Biochem. Sci. 28(6), 294-304 (2003).
7. Weir JP. Regulation of herpes simplex virus gene expression. Gene 271(2), 117-130 (2001).
8. Stevens JG, Wagner EK, Devi-Rao GB, Cook ML, Feldman LT. RNA complementary to a herpes virus a gene mRNA is prominent in latently infected neurons. Science 235(4792), 1056-1059 (1987).
9. Sawtell NM. Comprehensive quantification of herpes simplex virus latency at the single-cell level. J. Virol. 71(7), 5423-5431 (1997).
10. Sawtell NM. The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia. J. Virol. 72(8), 6888-6892 (1998).
11. Sawtell NM. Quantitative analysis of herpes simplex virus reactivation in vivo demonstrates that reactivation in the nervous system is not inhibited at early times postinoculation. J. Virol. 77(7), 4127-4138 (2003).
12. Sawtell NM, Thompson RL. Comparison of herpes simplex virus reactivation in ganglia in vivo and in explants demonstrates quantitative and qualitative differences. J. Virol. 78(14), 7784-7794 (2004).
13. Sawtell NM, Thompson RL, Haas RL. Herpes simplex virus DNA synthesis is not a decisive regulatory event in the initiation of lytic viral protein expression in neurons in vivo during primary infection or reactivation from latency. J. Virol. 80(1), 38-50 (2006).
14. Whitley RJ. Herpes simplex virus infection. Semin. Pediatr. Infect. Dis. 13(1), 6-11 (2002).
15. Thompson RL, Sawtell NM. Herpes simplex virus type 1 latency-associated transcript gene promotes neuronal survival. J. Virol. 75(14), 6660-6675 (2001).
16. Sawtell NM. Thompson RL. Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J. Virol. 66(4), 2150-2156 (1992).
17. Preston CM, Frame MC, Campbell ME. A complex formed between cell components and an HSV structural polypeptide binds to a viral immediate early gene regulatory DNA sequence. Cell 52(3), 425-434 (1988).
18. Kristie TM, Roizman B. Host cell proteins bind to the cis-acting site required for virion-mediated induction of herpes simplex virus 1 a genes. Proc Natl Acad Sci USA 84(1), 71-75 (1987).
19. Stern S, Tanaka M, Herr W. The Oct-1 homoeodomain directs formation of a multiprotein-DNA complex with the HSV transactivator VP16. Nature 341(6243), 624-630 (1989).
20. Triezenberg SJ, Lamarco KL, Mcknight SL. Evidence of DNA: protein interactions that mediate HSV-1 immediate early gene activation by VP16. Genes Dev. 2(6), 730-742 (1988).
21. Sears AE, Hukkanen V, Labow MA, Levine AJ, Roizman B. Expression of the herpes simplex virus 1 a transinducing factor (VP16) does not induce reactivation of latent virus or prevent the establishment of latency in mice. J. Virol. 65(6), 2929-2935 (1991).
22. Ace CI, Mckee TA, Ryan JM, Cameron JM, Preston CM. Construction and characterization of a herpes simplex virus type 1 mutant unable to transinduce immediate-early gene expression. J. Virol. 63(5), 2260-2269 (1989).
23. Steiner I, Spivack JG, Deshmane SL, Ace CI, Preston CM, Fraser NW. A herpes simplex virus type 1 mutant containing a nontransinducing Vmw65 protein establishes latent infection in vivo in the absence of viral replication and reactivates efficiently from explanted trigeminal ganglia. J. Virol. 64(4), 1630-1638 (1990).
24. Valyi-Nagy T, Deshmane SL, Raengsakulrach B et al. Herpes simplex virus type 1 mutant strain IN1814 establishes a unique, slowly progressing infection in SCID mice. J. Virol. 66(12), 7336-7345 (1992).
25. Ecob-Prince MS, Rixon FJ, Preston CM, Hassan K, Kennedy PG. Reactivation in vivo and in vitro of herpes simplex virus from mouse dorsal root ganglia which contain different levels of latency-associated transcripts. J. Gen. Virol. 74(Pt 6), 995-1002 (1993).
26. Katz JP, Bodin ET, Coen DM. Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants. J. Virol. 64(9), 4288-4295 (1990).
27. Sawtell NM, Thompson RL. Herpes simplex virus type 1 latency-associated transcription unit promotes anatomical site-dependent establishment and reactivation from latency. J. Virol. 66(4), 2157-2169 (1992).
28. Cai W, Astor TL, Liptak LM, Cho C, Coen DM, Schaffer PA. The herpes simplex virus type 1 regulatory protein ICP0 enhances virus replication during acute infection and reactivation from latency. J. Virol. 67(12), 7501-7512 (1993).
29. Halford WP, Schaffer PA. ICP0 is required for efficient reactivation of herpes simplex virus type 1 from neuronal latency. J. Virol. 75(7), 3240-3249 (2001).
30. Knickelbein JE, Khanna KM, Yee MB, Baty CJ, Kinchington PR, Hendricks RL. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 322(5899), 268-271 (2008).
31. Kosz-Vnenchak M, Jacobson J, Coen DM, Knipe DM. Evidence for a novel regulatory pathway for herpes simplex virus gene expression in trigeminal ganglion neurons. J. Virol. 67(9), 5383-5393 (1993).
32. Thompson RL, Rogers SK, Zerhusen MA. Herpes simplex virus neurovirulence and productive infection of neural cells is associated with a function which maps between 0.82 and 0.832 map units on the HSV genome. Virology 172(2), 435-450 (1989).
33. Thompson RL, Sawtell NM. Evidence that the herpes simplex virus type 1 ICP0 protein does not initiate reactivation from latency in vivo. J. Virol. 80(22), 10919-10930 (2006).
34. Thompson RL, Shieh MT, Sawtell NM. Analysis of herpes simplex virus ICP0 promoter function in sensory neurons during acute infection, establishment of latency, and reactivation in vivo. J. Virol. 77(22), 12319-12330 (2003).
35. Thompson RL, Preston CM, Sawtell NM. De novo synthesis of VP16 coordinates the exit from HSV latency in vivo. PLoS Pathog. 5(3), e1000352 (2009).
36. Hufner K, Derfuss T, Herberger S et al. Latency of a-herpes viruses is accompanied by a chronic inflammation in human trigeminal ganglia but not in dorsal root ganglia. J. Neuropathol. Exp. Neurol. 65(10), 1022-1030 (2006).
37. Tyler KL. Herpes simplex virus infections of the central nervous system: encephalitis and meningitis, including mollaret's. Herpes 11(Suppl. 2), 57A-64A (2004).
38. Hukkanen V, Broberg E, Salmi A, Eralinna JP. Cytokines in experimental herpes simplex virus infection. Int. Rev. Immunol. 21(4-5), 355-371 (2002).
39. Fleer A, Krediet TG. Innate immunity: toll-like receptors and some more. A brief history, basic organization and relevance for the human newborn. Neonatology 92(3), 145-157 (2007).
40. Rouse BT, Kaistha SD. A tale of 2 a-herpesviruses: lessons for vaccinologists. Clin. Infect. Dis. 42(6), 810-817 (2006).
41. Yarlagadda SG, Perazella MA. Drug-induced crystal nephropathy: an update. Expert Opin. DrugSaf. 7(2), 147-158 (2008).
42. Liang Y, Vogel JL, Narayanan A, Peng H, Kristie TM. Inhibition of the histone demethylase LSD1 blocks a -herpesvirus lytic replication and reactivation from latency. Nat. Med. 15(11), 1312-1317 (2009).
43. Haigh A, Greaves R, O'Hare P. Interference with the assembly of a virus-host transcription complex by peptide competition. Nature 344(6263), 257-259 (1990).
44. Lai JS, Herr W. Interdigitated residues within a small region of VP16 interact with Oct-1, HCF and DNA. Mol. Cell Biol. 17(7), 3937-3946 (1997).
45. Kuo YC, Kuo YH, Lin YL, Tsai WJ. Yatein from Chamaecyparis obtusa suppresses herpes simplex virus type 1 replication in HeLa cells by interruption the immediate-early gene expression. Antiviral Res. 70(3), 112-120 (2006).
46. Kuo YC, Lin LC, Tsai WJ, Chou CJ, Kung SH, Ho YH. Samarangenin b from Limonium sinense suppresses herpes simplex virus type 1 replication in Vero cells by regulation of viral macromolecular synthesis. Antimicrob. Agents Chemother. 46(9), 2854-2864 (2002).
47. Lin LC, Kuo YC, Chou CJ. Anti-herpes simplex virus type-1 flavonoids and a new flavanone from the root of limonium sinense. Planta Med. 66(4), 333-336 (2000).
48. Deshmane SL, Fraser NW. During latency, herpes simplex virus type 1 DNA is associated with nucleosomes in a chromatin structure. J. Virol. 63(2), 943-947 (1989).
49. Knipe DM, Cliffe A. Chromatin control of herpes simplex virus lytic and latent infection. Nat. Rev. Microbiol. 6(3), 211-221 (2008).
50. Pankiewicz R, Karlen Y, Imhof MO, Mermod N. Reversal of the silencing of tetracycline-controlled genes requires the coordinate action of distinctly acting transcription factors. J. Gene Med. 7(1), 117-132 (2005).